GPC3 reduces cell proliferation in renal carcinoma cell lines

BackgroundGlypican 3 (GPC3) is a member of the family of glypican heparan sulfate proteoglycans (HSPGs). The GPC3 gene may play a role in controlling cell migration, negatively regulating cell growth and inducing apoptosis. GPC3 is downregulated in several cancers, which can result in uncontrolled cell growth and can also contribute to the malignant phenotype of some tumors. The purpose of this study was to analyze the mechanism of action of the GPC3 gene in clear cell renal cell carcinoma.MethodsFive clear cell renal cell carcinoma cell lines and carcinoma samples were used to analyze GPC3 mRNA expression (qRT-PCR). Then, representative cell lines, one primary renal carcinoma (786-O) and one metastatic renal carcinoma (ACHN), were chosen to carry out functional studies. We constructed a GPC3 expression vector and transfected the renal carcinoma cell lines, 786-O and ACHN. GPC3 overexpression was analyzed using qRT-PCR and immunocytochemistry. We evaluated cell proliferation using MTT and colony formation assays. Flow cytometry was used to evaluate apoptosis and perform cell cycle analyses.ResultsWe observed that GPC3 is downregulated in clear cell renal cell carcinoma samples and cell lines compared with normal renal samples. GPC3 mRNA expression and protein levels in 786-O and ACHN cell lines increased after transfection with the GPC3 expression construct, and the cell proliferation rate decreased in both cell lines following overexpression of GPC3. Further, apoptosis was not induced in the renal cell carcinoma cell lines overexpressing GPC3, and there was an increase in the cell population during the G1 phase in the cell cycle.ConclusionWe suggest that the GPC3 gene reduces the rate of cell proliferation through cell cycle arrest during the G1 phase in renal cell carcinoma.

[1]  Z. Yao,et al.  Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. , 2012, World journal of gastroenterology.

[2]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[3]  Y. Iwamoto,et al.  Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression. , 2013, Human pathology.

[4]  D. Schlessinger,et al.  Frequent silencing of the GPC3 gene in ovarian cancer cell lines. , 1999, Cancer research.

[5]  T. Nakatsura,et al.  A glypican-3-derived peptide vaccine against hepatocellular carcinoma , 2012, Oncoimmunology.

[6]  H. Kajiyama,et al.  Gene silencing of glypican‐3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo , 2010, Cancer science.

[7]  Xin Ma,et al.  LncRNAs Expression Signatures of Renal Clear Cell Carcinoma Revealed by Microarray , 2012, PloS one.

[8]  H. Moch.  An overview of renal cell cancer: pathology and genetics. , 2013, Seminars in cancer biology.

[9]  S. Ishikawa,et al.  Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signaling , 2003, International journal of cancer.

[10]  Mitchell Ho,et al.  Glypican-3: a new target for cancer immunotherapy. , 2011, European journal of cancer.

[11]  F. Waldman,et al.  Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.

[12]  G. Yousef,et al.  Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. , 2012, Cancer research.

[13]  Z. Shriver,et al.  Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. , 2002, Seminars in thrombosis and hemostasis.

[14]  H. M. Garay-Malpartida,et al.  Glypican-3 reexpression regulates apoptosis in murine adenocarcinoma mammary cells modulating PI3K/Akt and p38MAPK signaling pathways , 2010, Breast Cancer Research and Treatment.

[15]  Min Liu,et al.  Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma , 2012, Journal of Translational Medicine.

[16]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[17]  O. Yoshie,et al.  Metastatic potential of murine B16 melanoma correlates with reduced surface heparan sulfate glycosaminoglycan. , 1987, Japanese journal of cancer research : Gann.

[18]  Shanshan Wang,et al.  Notch1 activation promotes renal cell carcinoma growth via PI3K/Akt signaling , 2012, Cancer science.

[19]  D. Thompson,et al.  The burden of illness associated with hepatocellular carcinoma in the United States. , 2009, Journal of hepatology.

[20]  Yusuke Nakamura,et al.  Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma. , 2006, International journal of oncology.

[21]  J. Filmus,et al.  Glypican-3 expression is silenced in human breast cancer , 2001, Oncogene.

[22]  Tao Liu,et al.  Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells. , 2012, Biochemical and biophysical research communications.

[23]  T. Longacre,et al.  Oncofetal Protein Glypican-3 Distinguishes Yolk Sac Tumor From Clear Cell Carcinoma of the Ovary , 2008, The American journal of surgical pathology.

[24]  H. Asamura,et al.  Utility of 10 Immunohistochemical Markers Including Novel Markers (Desmocollin-3, Glypican 3, S100A2, S100A7, and Sox-2) for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  Mitchell Ho,et al.  The role of glypican-3 in regulating Wnt in hepatocellular carcinomas. , 2011, Cancer reports.

[26]  K. Okoń.  Glypican-3 is expressed in chromophobe renal cell carcinomas. , 2008, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[27]  H. Friess,et al.  Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders , 2001, Gut.

[28]  R. Sanderson,et al.  Heparan sulfate proteoglycans in invasion and metastasis. , 2001, Seminars in cell & developmental biology.

[29]  L. Sullivan,et al.  Immunohistochemical Expression of Glypican-3 in Pediatric Tumors: An Analysis of 414 Cases , 2013, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[30]  A. Bell,et al.  Suppression of liver regeneration and hepatocyte proliferation in hepatocyte‐targeted glypican 3 transgenic mice , 2010, Hepatology.

[31]  M. Peters,et al.  Inhibition of Invasion and Metastasis by Glypican-3 in a Syngeneic Breast Cancer Model , 2003, Breast Cancer Research and Treatment.

[32]  M. Tsao,et al.  Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma , 2008, Modern Pathology.

[33]  J. Doré,et al.  Accumulation of heparan sulfate in the culture of human melanoma cells with different metastatic ability , 1993, Clinical & Experimental Metastasis.

[34]  K. Furge,et al.  Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Jing He,et al.  Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. , 2011, Neoplasia.

[36]  Ning Li,et al.  Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. , 2012, Acta histochemica.

[37]  D. Thompson,et al.  The burden of illness associated with renal cell carcinoma in the United States. , 2007, Urologic oncology.

[38]  A. Bell,et al.  Hepatocyte proliferation and hepatomegaly induced by phenobarbital and 1,4‐bis [2‐(3,5‐dichloropyridyloxy)] benzene is suppressed in hepatocyte‐targeted glypican 3 transgenic mice , 2011, Hepatology.

[39]  B. Drucker,et al.  Renal cell carcinoma: current status and future prospects. , 2005, Cancer treatment reviews.

[40]  Xiao-li Zhang,et al.  Oncogenic activation of glypican‐3 by c‐Myc in human hepatocellular carcinoma , 2012, Hepatology.

[41]  Michael P. Gailey,et al.  Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (ΔNp63) in squamous cell and urothelial carcinoma. , 2013, American journal of clinical pathology.

[42]  M. Viti,et al.  Structure and properties of an under-sulfated heparan sulfate proteoglycan synthesized by a rat hepatoma cell line , 1984, The Journal of cell biology.

[43]  Hui Liu,et al.  Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. , 2010, World journal of gastroenterology.

[44]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[45]  Osamu Ukimura,et al.  Treatment of localised renal cell carcinoma. , 2011, European urology.

[46]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[47]  Liang Cheng,et al.  Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. , 2007, Analytical and quantitative cytology and histology.

[48]  Hui-lai Miao,et al.  Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down‐regulation of YAP , 2013, Journal of cellular biochemistry.

[49]  Wen Shi,et al.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.

[50]  M. Kim,et al.  Blocking endogenous glypican-3 expression releases Hep 3B cells from G1 arrest. , 2003, Molecules and cells.

[51]  S. Jhanwar,et al.  Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma , 2000, Oncogene.